Stocks · Health care · Services-Medical Laboratories

Natera, Inc.

NTRA Clue Score53
United States Fiscal year ends December CIK 0001604821 Results filed 5 Nov 2026

What the insiders did Scheduled selling only

Insider
Date
Role
Action
Shares
Price
Amount
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
2,000
$408.24
$816.47K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
3,800
$407.27
$1.55M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
1,400
$406.63
$569.28K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
6,274
$405.18
$2.54M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
10,321
$404.64
$4.18M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
3,858
$403.27
$1.56M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
6,309
$402.23
$2.54M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
5,974
$401.42
$2.40M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
2,671
$400.31
$1.07M
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
793
$399.31
$316.66K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
600
$398.09
$238.85K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
1,100
$397.16
$436.88K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
1,900
$396.30
$752.98K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
300
$394.40
$118.32K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
800
$393.47
$314.78K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
300
$391.58
$117.47K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
600
$390.21
$234.12K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
714
$389.84
$278.35K
Matthew Rabinowitz
15 Oct 2026
Executive Chairman
Sold after exercise
286
$388.32
$111.06K

What was left out

Form 4 filings counted 19
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 62
Sales straight out of an exercise 19
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 56,000
History held since 7 Jul 2015